News & Events
Announcements
18 March 2013
Proacta CEO to Speak at NZ BIO Annual Conference, Auckland, March 2013
30 August 2012
Proacta Incorporated Announces first patient treated in PR610 clinical trial
28 August 2012
Proacta Incorporated Announces IND Approval for PR610
13 December 2011
PR104 Acute Leukemia study presented at 53rd annual meeting of the American Society of Hematology
24 August 2011
TV7 in New Zealand releases documentary on Proacta's HSMKI program
22 February 2011
Proacta Incorporated and Yakult Honsha Announce an Agreement for the Collaborative Research, Development and Commercialization of PR509
1 December 2010
Proacta receives $489,000 from US government stimulus for biotechnology
10 February 2010
Proacta Founding Scientist to Speak at AACR 101st Annual Meeting
1 February 2010
Proacta Updates the PR104 Phase II Program
15 November 2009
Proacta to present at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
31 March 2009
Proacta Announces Phase II Clinical Trial of PR104
30 September 2008
Proacta appoints Kevin de la Torre as Chief Financial Officer
1 August 2008
Proacta announces promotion of John Gutheil, MD to Chief Executive Officer
7 February, 2007
Proacta completes $35M series B financing
17 May, 2006
John Gutheil MD, joins Proacta as Chief Medical Officer and Senior Vice President of Clinical Affairs
24 January, 2006
Proacta Announces Phase I Clinical Trial of Novel Prodrug to Target Hypoxic Tumors
3 March, 2005
Proacta awarded NZ$3.45m grant funding for development pipeline
1 October, 2004
Proacta reports data at the 16th EORTC-NCI-AACR Meeting
16 August, 2004
Proacta Inc, Anti-Cancer Start Up, appoints Paul Cossum as CEO
24 June, 2004
Proacta Inc, Anti-Cancer Start Up, Raises $US8 in series A funding
